Research Topics
Species | Marina Y KonoplevaSummaryAffiliation: The University of Texas Country: USA Publications
| Collaborators
|
Detail Information
Publications
Leukemia stem cells and microenvironment: biology and therapeutic targetingMarina Y Konopleva
The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
J Clin Oncol 29:591-9. 2011..New strategies that exploit potentially unique properties of the LSCs and their microenvironment are discussed...
Targeting the leukemia microenvironmentMarina Konopleva
Section of Molecular Hematology and Therapy and Department of Stem Cell Transplantation and Cellular Therapies, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Curr Drug Targets 8:685-701. 2007..Focus on this stroma-leukemia crosstalk may result in the development of strategies that alleviate the acquisition of a chemoresistant phenotype and enhance the efficacy of therapies in hematological malignancies...- Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approachesMarina Konopleva
Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Drug Resist Updat 12:103-13. 2009..This complex interplay provides a rationale for appropriately tailored molecular therapies targeting not only leukemic cells but also their microenvironment to ensure improved outcomes in leukemia... 
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemiaFarhad Ravandi
Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
J Clin Oncol 28:1856-62. 2010..Plasma inhibitory assay demonstrated an on-target effect on FLT3 kinase activity. CONCLUSION Sorafenib can be safely combined with chemotherapy, produces a high CR rate in FLT3-mutated patients, and inhibits FLT3 signaling...- Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemiaSteven M Kornblau
Section of Molecular Hematology and Therapy, Unit 448, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Blood 108:2358-65. 2006..It is thus likely that only combinations of agents that target the multiply activated STPs will be beneficial for patients with AML... - Antidiabetic therapies affect risk of pancreatic cancerDonghui Li
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Gastroenterology 137:482-8. 2009..We investigated the effect of antidiabetic therapies on the risk of pancreatic cancer... - Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimenMary Ann Weiser
Department of General Internal Medicine, Ambulatory Treatment and Emergency Care, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 100:1179-85. 2004.... - Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phaseJorge E Cortes
Departments of Leukemia and Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 28:392-7. 2010..Although most patients with chronic myeloid leukemia (CML) in chronic phase respond well to front-line therapy with imatinib, some patients do not achieve the desirable end point, and others may eventually lose response or are intolerant... - Apoptosis in leukemias: regulation and therapeutic targetingIsmael Samudio
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Cancer Treat Res 145:197-217. 2010..This chapter will review our understanding of the molecular circuitry that controls apoptosis in leukemia and the pharmacological manipulations of this pathway that may yield therapeutic benefit... - Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemiaMarina Konopleva
Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer Cell 10:375-88. 2006..These data suggest that ABT-737 could be a highly effective antileukemia agent when the mechanisms of resistance identified here are considered... - 2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancerIsmael Samudio
Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
J Biol Chem 280:36273-82. 2005..These results suggest that CDDO and its derivatives may offer a clinical benefit for the treatment of PC... - MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapyKensuke Kojima
Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 448, Houston, TX 77030, USA
Blood 106:3150-9. 2005..p53 activation by targeting the p53-MDM2 interaction might offer a novel therapeutic strategy for AML that retain wild-type p53... - Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax)Marina Konopleva
Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Cancer Res 68:3413-20. 2008..In conclusion, we show that obatoclax potently induces apoptosis and decreases leukemia cell proliferation and may be used in a novel therapeutic strategy for AML alone and in combination with other targeted agents and chemotherapeutics... - The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cellsMarina Konopleva
Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Br J Haematol 118:521-34. 2002..These findings could be used in the development of therapies that selectively induce apoptosis in quiescent leukaemic progenitor cells... - Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNKAlina Felicia Nica
Institute of Molecular Medicine, University of Texas Health Science Center, Houston, Texas, USA
Cell Cycle 7:3362-70. 2008..The findings presented here suggest that Caspase-8, JNK, and perhaps MCL-1 may play important roles in regulating cell death and may represent new targets for therapeutic strategies for CML... - Drug-resistant breast carcinoma (MCF-7) cells are paradoxically sensitive to apoptosisJack S K Chen
Department of Bioimmunotherapy, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA
J Cell Physiol 200:223-34. 2004.... - The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemiaMarina Konopleva
Section of Molecular Hematology and Therapy and the Department of Blood and Marrow Transplantation at The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
Cancer Res 64:7927-35. 2004..The direct modulation of mitochondrial-mediated, caspase-independent apoptosis by CDDO may be advantageous for overcoming chemoresistance in AML... - Mechanisms of drug resistance in AMLMichael Andreeff
Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Cancer Treat Res 112:237-62. 2002 - Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemiaMarina Konopleva
Department of Blood and Marrow Transplantation, Section of Molecular Hematology and Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
Blood 99:326-35. 2002..Differential effects of CDDO-Me on leukemic and normal progenitor cells suggest that CDDO-Me has potential as a novel compound in the treatment of hematologic malignancies... - Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AMLZhihong Zeng
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Blood 113:6215-24. 2009..Disruption of these interactions with CXCR4 inhibitors represents a novel strategy of sensitizing leukemic cells by targeting their protective bone marrow microenvironment... - PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APLYoko Tabe
Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Cancer Biol Ther 6:1967-77. 2007..In summary, these results provide rationale for the combined targeting of RAR and PPARgamma nuclear receptors in the therapy of APL... - Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cellsIsmael Samudio
Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Mol Cancer Ther 7:1130-9. 2008..CDDO-Me is in clinical trials and shows signs of clinical activity, with minimal side effects and complete lack of cardiotoxicity. Studies in leukemias are in preparation... - Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cellsYoko Tabe
Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer Res 67:684-94. 2007.... - Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AMLKensuke Kojima
Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Cell Cycle 5:2778-86. 2006..Our data suggest that combined targeting of Mdm2 and Bcl-2 proteins could offer considerable therapeutic promise in AML... - Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis inductionIsmael Samudio
Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
J Clin Invest 120:142-56. 2010..The results support the concept of FAO inhibitors as a therapeutic strategy in hematological malignancies... - Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistanceBing Z Carter
The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Cell Cycle 5:2223-9. 2006..Therefore, Eg5 could be a potential therapeutic target for the treatment of BC CML, in particular Imatinib-resistant BC CML... - PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoterYoko Tabe
Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1400 Holcombe Boulevard, Unit 448, Houston, TX 77030, USA
Ann Hematol 85:689-704. 2006..These results demonstrate that oncogenic PML-RARalpha and AML1-ETO translocations are rarely associated with RARbeta2 promoter methylation in primary AML samples... - A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cellsShishir Shishodia
Cytokine Research Laboratory, Department of Experimental Therapeutics, Department of Blood and Marrow Transplantation, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 12:1828-38. 2006.... - Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemiaMichele Milella
Department of Blood and Marrow Transplantation, Section of Molecular Hematology and Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Blood 99:3461-4. 2002..These findings show that the Bcl-2 and MAPK pathways are relevant molecular targets in AML and that their concurrent inhibition could be developed into a new therapeutic strategy for this disease... - PML-RARalpha is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survivalYoko Tabe
Department of Blood and Marrow Transplantation, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
Blood 103:1815-22. 2004..This report provides a mechanistic basis for the BM adipocyte-leukemia cell interaction and suggests that OB-R receptor blockade may have therapeutic use in APL... - Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemiasMarina Konopleva
Section of Molecular Hematology and Therapy and Department of Blood and Marrow Transplantation, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
Mol Cancer Ther 3:1249-62. 2004.... - Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cellsYoko Tabe
Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, Unit 448, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Blood 107:1546-54. 2006.... - Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cellsMarina Konopleva
Department of Blood and Marrow Transplantation, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer Res 65:9962-70. 2005..This DeltaRaf:ER system can serve as a preclinical model to evaluate the effects of signal transduction inhibitors which target the Raf and MEK proteins... - Guggulsterones induce apoptosis and differentiation in acute myeloid leukemia: identification of isomer-specific antileukemic activities of the pregnadienedione structureIsmael Samudio
Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Unit 448, 1400 Holcombe Boulevard, Houston, TX 77030, USA
Mol Cancer Ther 4:1982-92. 2005.... - Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemiaTwee Tsao
Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Cancer Res 70:4949-60. 2010.... - Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and BimWeiguo Zhang
Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
Cancer Res 70:2424-34. 2010..These results strongly indicate the therapeutic potential of combined MEK/MDM2 blockade in AML and implicate Puma and Bim as major regulators of AML cell survival... - Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemiaKensuke Kojima
Department of Blood and Marrow Transplantation, Section of Molecular Hematology and Therapy, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, 77030, USA
Blood 108:993-1000. 2006..Results suggest that the nongenotoxic activation of p53 by targeting the Mdm2-p53 interaction provides a novel therapeutic strategy for CLL... - Spontaneous migration of acute promyelocytic leukemia cells beneath cultured bone marrow adipocytes with matched expression of the major histocompatibility complexYoko Tabe
Blood and Marrow Transplantation, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
Rinsho Byori 52:642-8. 2004..This match in MHC expression may play a role in the intimate cell-to-cell interactions that support the anti-apoptotic effects of the membrane-bound leptin signaling pathway... - Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cellsDuncan H Mak
Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Mol Cancer Ther 8:2509-16. 2009.... - Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survivalGiuseppe Monaco
Department of Human Genetics, Baylor College of Medicine, Houston, Texas, USA
Stem Cells 22:188-201. 2004..In conclusion, we demonstrated that CXCR4 is not critical for the engraftment of AML CD34+ cells in NOD/SCID mice. The model may, however, reflect the clinical course of the disease... - Growth-inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor-gamma expressionBohuslav Melichar
Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
Gynecol Oncol 93:149-54. 2004..The activity of CDDO in platinum-resistant cell lines is encouraging with respect to the potential clinical use of the drug... - Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AMLZhihong Zeng
Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Blood 109:3509-12. 2007..Our study provides the first evidence that rapamycin derivatives inhibit AKT signaling in primary AML cells both in vitro and in vivo, and supports the therapeutic potential of mTOR inhibition strategies in leukemias... - Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemiasZhihong Zeng
Department of Blood and Marrow Transplantation, Section of Molecular Hematology and Therapy, Unit 448, 1515 Holcombe Boulevard, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
Mol Cancer Ther 5:3113-21. 2006..Disruption of these interactions by the peptide CXCR4 inhibitor RCP168 represents a novel strategy for targeting leukemic cells within the bone marrow microenvironment... - Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemiaWeiguo Zhang
Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
J Natl Cancer Inst 100:184-98. 2008..The kinase inhibitor sorafenib induces growth arrest and apoptosis at much lower concentrations in AML cell lines that harbor FLT3-ITD mutations than in AML cell lines with wild-type FLT3... - Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistanceJulianne M Davis
Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC 27858, USA
Clin Cancer Res 9:1161-70. 2003..These observations suggest both independent and overlapping roles for Raf-1 and Bcl-2 oncogenes in the resistance to growth inhibition by doxorubicin... - Expression of inducible Bcl-X(S) in myeloid leukemia: compensatory upregulation of Bcl-X(L) and Bcl-2 prevents apoptosis and chemosensitizationFrank Tacke
Department of Gastroenterology, Hepatology and Endocrinolog, Hannover Medical School, Hannover, Germany
Cancer Biol Ther 3:340-7. 2004..These results suggest the existence of a regulatory mechanism aimed to protect leukemic cells from pro-apoptotic stimuli... - MEK blockade converts AML differentiating response to retinoids into extensive apoptosisMichele Milella
Division of Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy
Blood 109:2121-9. 2007..Taken together, these results indicate that combined retinoid treatment and MEK blockade exert powerful antileukemic effects and could be developed into a novel therapeutic strategy for both AML and APL... - Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptorsAaron D Schimmer
Burnham Institute for Medical Research, La Jolla, California 92037, USA
Cancer Res 66:2367-75. 2006.... - CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cellsLinhua Jin
Department of Clinical Pathology, Juntendo University School of Medicine, Tokyo, Japan
Mol Cancer Ther 7:48-58. 2008..Altogether, these findings suggest that the up-regulation of CXCR4 by imatinib promotes migration of CML cells to bone marrow stroma, causing the G0-G1 cell cycle arrest and hence ensuring the survival of quiescent CML progenitor cells... - A novel ring-substituted diindolylmethane,1,1-bis[3'-(5-methoxyindolyl)]-1-(p-t-butylphenyl) methane, inhibits extracellular signal-regulated kinase activation and induces apoptosis in acute myelogenous leukemiaRooha Contractor
Department of Blood and Marrow Transplantation, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA
Cancer Res 65:2890-8. 2005..Together, these findings suggest that diindolylmethanes are a new class of compounds that selectively induce apoptosis in AML cells through the modulation of the extracellular signal-regulated kinase and PPARgamma signaling pathways... - 2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid and related compounds inhibit growth of colon cancer cells through peroxisome proliferator-activated receptor gamma-dependent and -independent pathwaysSudhakar Chintharlapalli
Department of Biochemistry and Biophysics, Texas A and M University, College Station, TX 77843-4466, USA
Mol Pharmacol 68:119-28. 2005.... - Correlation between CXCR4 and homing or engraftment of acute myelogenous leukemiaGiuseppe Monaco
Cancer Res 64:6832 author reply 6832-3. 2004 - Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemiaKensuke Kojima
Department of Hematology, Wakayama Medical University, Wakayama, Japan
Blood 112:2886-95. 2008..Our findings provide the molecular rationale for concomitant targeting of Aurora kinases and Mdm2 in AML where TP53 mutations are rare and downstream p53 signaling is mostly intact...